First-line ART use by year of initiation (n = 4662).
- David Charles Boettiger (625230)
- Stephen Kerr (625231)
- Rossana Ditangco (361612)
- Tuti Parwati Merati (625232)
- Thuy Thi Thanh Pham (625233)
- Romanee Chaiwarith (427726)
- Sasisopin Kiertiburanakul (427725)
- Chung Ki Patrick Li (625234)
- Nagalingeswaran Kumarasamy (36007)
- Saphonn Vonthanak (625235)
- Christopher Lee (11627)
- Nguyen Van Kinh (129736)
- Sanjay Pujari (428216)
- Wing Wai Wong (625236)
- Adeeba Kamarulzaman (307011)
- Fujie Zhang (155391)
- Evy Yunihastuti (428215)
- Jun Yong Choi (290863)
- Shinichi Oka (205454)
- Oon Tek Ng (134833)
- Pacharee Kantipong (311441)
- Mahiran Mustafa (625237)
- Winai Ratanasuwan (427729)
- Annette Sohn (625238)
- Matthew Law (36008)
Publication date
September 2014
DOIAbstract
<p>a) Drug classes. NRTIs not represented as there was a single patient that initiated a regimen without an NRTI; b) NRTI. Not represented are didanosine (2.9% of patients overall) and zalcitabine (0.02%); c) NNRTI. Not represented is rilpivirine (0.13%); d) PI. Not represented are indinavir (0.66%), nelfinavir (0.39%), tipranavir (0.39%), saquinavir (0.17%), fosamprenavir (0.17%) and full-dose ritonavir (0.11%). ART = antiretroviral therapy; NRTI = nucleoside reverse transcriptase inhibitor; NNRTI = non-NRTI; PI = protease inhibitor; 3TC/FTC = lamivudine/emtricitabine; d4T = stavudine; AZT = zidovudine; TDF = tenofovir; ABC = abacavir; EFV = efavirenz; NVP = nevirapine; LPV = lopinavir; ATV = atazanavir; DRV = darunavir.</p
Add to ORKG